Together, we have over 50 years of experience in the medical device world, and we’ve developed a number of technologies that are already impacting people’s lives—including the Watchman cardiology device invented by our Chief Medical Officer, Dr. Robert Schwartz and purchased by Boston Scientific in 2011, and the Resonic cellulite treatment launched by our CEO, CFO and Executive Chairman and purchased by AbbVie in 2021.
We were formed when co-founders, Landy Toth and Dr. Robert Schwartz, combined their knowledge and expertise with one goal in mind: to establish greater visibility into the nervous system to provide safer, more accurate treatment.
Chief Executive Officer and Director
Ms. Bisson is a seasoned Life Sciences and MedTech executive with a proven track record. She has executed multiple successful IPOs and exits, including her previous role as Chief Financial Officer of Soliton, which was acquired by AbbVie in 2021 for approximately $550 Million. Ms. Bisson joined Autonomix Medical in July 2023 as Chief Executive Officer and Director. From January 2015 until June 2022, Ms. Bisson served as Chief Financial Officer of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics.
Prior to joining Soliton, Ms. Bisson worked as a financial and business development consultant as a shareholder in Condon & Company, PC, from 2009 through December 2014, where she advised a number of life science companies. From 2005 to 2009, Ms. Bisson served as the Chief Financial Officer and Vice President of Operations for Zeno Corporation, a medical device company focused on new technology in the aesthetics area. Ms. Bisson previously served as the Chief Financial Officer of Gulfstream Trading, Ltd., an international oil trading organization, from 2001 to 2005. From 1995 to 2001, Ms. Bisson held various positions with Drypers Corporation, a publicly traded multinational consumer products company, where she ultimately held the title of Vice President of Integrated Solutions and oversaw accounting, information technology and logistics for the U.S. operation.
Ms. Bisson began her career at Arthur Andersen, LLP as an auditor focused on consumer products companies. Ms. Bisson also serves as an advisor to Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates. Ms. Bisson is a Certified Public Accountant and holds a B.A. degree in Accounting from Baylor University.
Executive Chairman
Mr. Klemp is a serial entrepreneur with multiple successful exits through his career. Most recently, he was Chief Executive Officer of Soliton, Inc., a medical device company he co-founded, took public on Nasdaq in 2018 and which was acquired by AbbVie in 2021 for approximately $550 Million. Mr. Klemp joined Autonomix in January 2022 as Executive Chairman.
Additionally, Mr. Klemp is a Co-Founder of Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, and has served as its Chairman of the Board and Chief Executive Officer since July 2015 and as President since August 2017. From November 2011 to December 2020, Mr. Klemp served as Chief Executive Officer and then Executive Chairman on the Board of Directors of Soliton. Prior to Soliton, Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch.
Additionally, from 1987 to 2000, Mr. Klemp served as Chief Executive Officer and Chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies.
Chief Business Officer
Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated companies. Over the course of her career, she has a proven track record with translating vision to expand value proposition and creating successful go-to-market solutions.
Mrs. Cook joins Autonomix having most recently served as the Vice President of Marketing at MedShift, a technology company helping to drive growth and scale to medical device manufacturers and healthcare providers. Prior to MedShift, Mrs. Cook served as the Vice President of Marketing at Soliton, Inc. While at Soliton she was responsible for bringing forward-thinking vision and leadership to craft the brand, commercial strategy and commercial go-to-market plan that launched the novel cellulite and tattoo removal medical aesthetic device RESONIC, which played a pivotal role in Soliton being acquired by AbbVie for a $550 million enterprise valuation. Prior to Soliton, Mrs. Cook was the Director of Consumer Marketing and Marketing Communications at Apollo Endosurgery, Inc. where she led patient positioning, segmentation, research, advertising, and marketing operations for Apollo’s portfolio of Class II medical devices, the LapBand and Orbera Weight Loss Balloon. Other career appointments include Integrated Marketing Director at Real Chemistry (formerly W2O Group); Vice President at Stern Advertising; Account Director at Rosetta Marketing (acquired by Publicis Groupe/Razorfish); and Brand Account Director at Doner Advertising.
Mrs. Cook holds a Bachelor of Science in Business Administration and Marketing from Miami University, Oxford, Ohio.
Chief Medical Officer
Dr. Schwartz is a serial medical device inventor and developer of the Watchman™, a left atrial appendage closure device and proven one-time procedure that reduces the risk of stroke in non-valvular atrial fibrillation (NVAF) patients and the risk of bleeding that comes with a long-term oral anticoagulant use. The Watchman™ sold to Boston Scientific and has generated over $1 Billion in revenue.
Dr. Schwartz is a Co-Founder of Autonomix Medical and has served as Chief Medical Officer since June 2023, and served as Chief Executive Officer from February 2022 until June 2023. In addition to his role at Autonomix, Dr. Schwartz serves as President of the Jon DeHaan Center for Medical Innovation and was previously Director at the Center for Applied Vascular Biology and Interventions, Mayo Foundation. Dr. Schwartz has also served as Professor and Associate Professor at the Mayo Medical School. He holds Board Certifications on the National Board of Medical Examiners, American Board of Internal Medicine and the American Board of Internal Medicine, Cardiovascular Diseases, is a member of the Society of Atherosclerosis Imaging and holds professional memberships as Fellow of the American College of Cardiology, American Heart Association and The Society for Cardiac Angiography and Interventions. He is the recipient of various awards including the Andreas Gruentzig Award for Basic Research in Coronary Restenosis from the Thoraxcenter/European Society of Cardiology and over the course of his career, he has published numerous articles in peer review journals dealing with various topics in interventional cardiology.
Dr. Schwartz holds a Master’s Degree in Electrical Engineering, and his doctorate from the University of Colorado-Denver and continued his internship, residency, and Fellowship at the Mayo Graduate School of Medicine.
Chief Technology Officer
Mr. Toth is a mechanical engineer and medical device expert having developed and commercialized multiple wearable and interventional diagnostic medical technologies. He is a key inventor and is responsible for Autonomix’s development efforts to date.
Mr. Toth co-founded Autonomix in August 2014 and has served as Chief Technology Officer since that time. In addition to these efforts, he founded Tricord Holdings, LLC in 2012 and founded and served as Chief Technology Officer of LifeLens Technologies, Inc. since September 2016.
Mr. Toth has also been an employee of Davos Chemical Corporation since January 2011. Over the past 20 years, Mr. Toth has successfully commercialized medical device technologies within startup environments. His focus has been the development and commercialization of wearable and interventional diagnostic medical technologies. He has authored over 600 publications across 56 patent families and his portfolio has a grant rate greater than 70% after 2 years. Mr. Toth holds a MASc from the University of Toronto and a BASc from the University of Waterloo.
Chief Financial Officer
Mr. Smith is a seasoned Life Sciences and MedTech financial executive with extensive experience providing financial and business leadership to private and public companies. Mr. Smith joined Autonomix Medical in July 2023 as Chief Financial Officer. Prior to joining Autonomix, from June 2018 to September 2022, Mr. Smith served as the Corporate Controller and Vice-President of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics that was acquired by AbbVie, Inc. in December 2021 for approximately $550 Million.
From 2011 to 2018, Mr. Smith held various positions with InfuSystem Holdings, Inc., a national provider of infusion pumps and related services to the healthcare industry, where he served as Corporate Controller and Vice-President before a promotion to Chief Accounting Officer and Executive Vice President. From 2010 to 2011, Mr. Smith served as the Director of External Reporting of Syncreon Holdings, Inc., an international leader in global supply chain management. From 2006 to 2010, Mr. Smith served as the Director of Accounting and Financial Reporting of Champion Homes, Inc., a leader in the manufactured housing industry and one of the largest modular homebuilders in North America. From 2005 to 2006, Mr. Smith served as the Director of External Financial Reporting for Dura Automotive Systems, a Tier 1 international designer and manufacturer of automotive components headquartered in Auburn Hills, MI.
From 1999 to 2006, Mr. Smith served in various roles and divisions for Valeo, Inc., an international Tier 1 automotive supplier, including as Financial Controller and Treasurer of Valeo Distribution North America and Director of Accounting and Internal Controls for Valeo Wiper Systems, Valoe’s largest division in North America. He began his professional career as an auditor with Deloitte & Touche, LLP in 1995. Mr. Smith served on active duty in the United States Navy from 1987 through 1991 and the reserves until 1993. Mr. Smith is a Certified Public Accountant and a graduate of the University of Illinois where he holds a Bachelor of Science in Accounting.
Autonomix Medical, Inc.
21 Waterway Ave, Suite 300
The Woodlands, TX 77380
LEGAL DISCLAIMER
This presentation (the “presentation”) has been prepared for use by Autonomix Medical, Inc. (“Autonomix”) in connection with their proposed offering. This presentation is for information purposes only and is being provided to assist interested parties in making their own evaluation with respect to a potential investment, and for no other purpose. This presentation may not be reproduced or redistributed, in whole or in part, without the prior written consent of Autonomix. Autonomix does not make any representation or warranty as to the accuracy or completeness of the information contained in this presentation. This presentation is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in connection with the proposed offering and is not intended to form the basis of any investment decision. You should consult your own legal, regulatory, tax, business, financial and accounting advisors to the extent you deem necessary and must make your own investment decision and perform your own independent investigation and analysis of an investment in the transactions contemplated in this presentation.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION (“SEC”) NOR ANY STATE OR TERRITORIAL SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESENTATION IS TRUTHFUL OR COMPLETE.
FORWARD-LOOKING STATEMENTS
This presentation may include ‘’forward-looking statements.‘’ To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Autonomix Medicial, Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’ ‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’ ‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Autonomix are highly speculative. Investing in shares of Autonomix involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Autonomix intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Autonomix, the offering and any other related topics, please review the registration statement that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
USE OF DATA
The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. Autonomix assumes no obligation to update the information in this presentation.
Autonomix is committed to protecting your privacy. This Privacy Policy outlines our practices concerning the collection, use, and protection of your personal information when you visit our website or use our services.
1. Information We Collect
We may collect personal information that you voluntarily provide to us, including but not limited to:
We may also collect non-personal information, such as:
2. How We Use Your Information
We may use your personal information for various purposes, including but not limited to:
3. Cookies and Tracking Technologies
We use cookies and similar tracking technologies to collect information about your browsing behavior on our website. You can manage your cookie preferences through your browser settings.
4. Disclosure of Your Information
We may share your personal information with third parties under the following circumstances:
5. Your Rights
You have the right to:
6. Data Security
We take reasonable measures to protect your personal information from unauthorized access, disclosure, alteration, or destruction. However, no method of data transmission over the internet or electronic storage is entirely secure. Therefore, we cannot guarantee its absolute security.
7. Children’s Privacy
Our website and services are not intended for children under the age of 13. We do not knowingly collect personal information from children. If you believe that a child has provided us with their personal information, please contact us, and we will take appropriate steps to delete the information.
8. Changes to this Privacy Policy
We may update this Privacy Policy from time to time to reflect changes in our practices or for other operational, legal, or regulatory reasons. We encourage you to review this Privacy Policy periodically for any updates.
9. Contact Us
If you have any questions or concerns about this Privacy Policy or our data practices, please contact us at autonomix@jtcir.com.
1. Acceptance of Terms
By accessing and using this website, you agree to abide by these Terms and Conditions, as well as any applicable laws and regulations. If you do not agree with these terms, please refrain from using this website.
2. Use of Content
All content on this website, including but not limited to text, images, graphics, videos, and logos, is the property of Autonomix or its affiliates and is protected by intellectual property laws. You may not reproduce, distribute, or display any content without prior written permission.
3. User Conduct
You agree not to engage in any of the following activities while using this website:
4. Privacy Policy
Your use of this website is also governed by our Privacy Policy, which outlines how we collect, use, and protect your personal information. By using this website, you consent to the practices described in our Privacy Policy.
5. Links to Third-Party Websites
This website may contain links to third-party websites. These links are provided for convenience only, and Autonomix does not endorse or assume responsibility for the content or practices of these websites. Accessing third-party websites is at your own risk.
6. Disclaimer of Warranties
This website is provided “as is,” without any warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, or non-infringement. Autonomix does not warrant that the website will be error-free or uninterrupted.
7. Limitation of Liability
To the fullest extent permitted by law, Autonomix shall not be liable for any direct, indirect, incidental, consequential, or punitive damages arising out of or related to your use of this website. This includes but is not limited to any loss of data or profits.
8. Governing Law
These Terms and Conditions shall be governed by and construed in accordance with the laws of the United States. Any disputes arising under these terms shall be subject to the exclusive jurisdiction of the courts in the United States.
9. Changes to Terms and Conditions
Autonomix reserves the right to modify or revise these Terms and Conditions at any time. It is your responsibility to review this page periodically for updates. Your continued use of the website after any changes signifies your acceptance of the revised terms.
10. Contact Information
If you have any questions or concerns about these Terms and Conditions, please contact us at autonomix@jtcir.com.